Our analysis pipeline has shed light on a common signature of 49 proteins in EVs from primary and model BC cells: the two proteins that were studied for experimental validation (COL1A2 and KRT2) agreed with the in-silico findings. This evidence concerns the gene COL1A2 and breast cancer.